Frequency and clinical implications of findings on true whole‐body <scp>18F</scp>‐<scp>FDG PET</scp> in the assessment of breast cancer

In the assessment of breast cancer, a true whole-body PET/CT can reveal metastases outside the limited whole-body FOV, but these are unlikely to be encountered in isolation and therefore may have little bearing on clinical stage or management. Ultimately, while the choice of FOV should still be based on the individual patient situation, routine utilisation of the true whole-body FOV in the asymptomatic patient may not be necessary.